Literature DB >> 20047147

The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.

Brooke M VandenBrink1, Nina Isoherranen.   

Abstract

The irreversible inhibition of cytochrome P450 (CYP) enzymes can cause significant drug-drug interactions (DDIs). The formation of metabolites is fundamental for the inactivation of CYP enzymes. Of the 19 CYP enzyme inactivators for which the mechanism of action has been established, 10 have circulating metabolites, which are on the metabolic pathway to inactivation of the CYP enzyme. Because inactivation of CYP enzymes usually requires multiple metabolic steps, the prediction of interactions between metabolites and CYPs in vivo may require complex models and the availability of data generated in vitro from each metabolite. Data discussed in this review suggest that circulating metabolites are more important in CYP inhibition in vivo than has been acknowledged.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047147      PMCID: PMC2898504     

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  95 in total

1.  A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine.

Authors:  C E Wright; T A Lasher-Sisson; R C Steenwyk; C N Swanson
Journal:  Pharmacotherapy       Date:  1992       Impact factor: 4.705

2.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; E Skjelbo
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

3.  The mechanism of the interaction between amiodarone and warfarin in humans.

Authors:  L D Heimark; L Wienkers; K Kunze; M Gibaldi; A C Eddy; W F Trager; R A O'Reilly; D A Goulart
Journal:  Clin Pharmacol Ther       Date:  1992-04       Impact factor: 6.875

4.  The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.

Authors:  K Kobayashi; T Yamamoto; K Chiba; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

5.  Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects.

Authors:  H K Kroemer; H Echizen; H Heidemann; M Eichelbaum
Journal:  J Pharmacol Exp Ther       Date:  1992-03       Impact factor: 4.030

6.  Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats.

Authors:  S Ohmori; I Ishii; S Kuriya; T Taniguchi; T Rikihisa; S Hirose; Y Kanakubo; M Kitada
Journal:  Drug Metab Dispos       Date:  1993 Mar-Apr       Impact factor: 3.922

7.  Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450.

Authors:  J C Stevens; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1993-08       Impact factor: 4.030

8.  Cytochrome P-455 nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver.

Authors:  K H Jönsson; B Lindeke
Journal:  Chirality       Date:  1992       Impact factor: 2.437

9.  Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.

Authors:  M He; K L Kunze; W F Trager
Journal:  Drug Metab Dispos       Date:  1995-06       Impact factor: 3.922

10.  Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs.

Authors:  C Bensoussan; M Delaforge; D Mansuy
Journal:  Biochem Pharmacol       Date:  1995-03-01       Impact factor: 5.858

View more
  14 in total

1.  Risk assessment of mechanism-based inactivation in drug-drug interactions.

Authors:  Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

2.  In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8).

Authors:  Chia Yong Pang; Joon Wah Mak; Rusli Ismail; Chin Eng Ong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-04       Impact factor: 3.000

3.  Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.

Authors:  Yoshiyuki Shirasaka; Jennifer E Sager; Justin D Lutz; Connie Davis; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2013-04-25       Impact factor: 3.922

4.  P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.

Authors:  Matthew G McDonald; Nicholas T Au; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

5.  Multienzyme Kinetics and Sequential Metabolism.

Authors:  Larry C Wienkers; Brooke M Rock
Journal:  Methods Mol Biol       Date:  2021

6.  A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?

Authors:  Yuan Wei; Chenxiao Tang; Vinayak Sant; Song Li; Samuel M Poloyac; Wen Xie
Journal:  Curr Pharmacol Rep       Date:  2016-05-04

7.  Numerical Analysis of Time-Dependent Inhibition by MDMA.

Authors:  John T Rodgers; Jeffrey P Jones
Journal:  Drug Metab Dispos       Date:  2019-10-22       Impact factor: 3.922

8.  Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System.

Authors:  Xiaojing Wang; Minghua Sun; Connie New; Spencer Nam; Wesley P Blackaby; Alastair J Hodges; David Nash; Mizio Matteucci; Joseph P Lyssikatos; Peter W Fan; Suzanne Tay; Jae H Chang
Journal:  ACS Med Chem Lett       Date:  2015-07-12       Impact factor: 4.345

Review 9.  Gemfibrozil in Combination with Statins-Is It Really Contraindicated?

Authors:  Barbara S Wiggins; Joseph J Saseen; Pamela B Morris
Journal:  Curr Atheroscler Rep       Date:  2016-04       Impact factor: 5.113

10.  Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Mol Pharm       Date:  2018-04-10       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.